First personalized cancer vaccine cuts recurrence risk in major trial

A major trial of a personalized mRNA cancer vaccine shows a significant reduction in disease recurrence, marking a potential turning point in cancer treatment. The results, reported by BBC News, are preliminary and not yet peer-reviewed, but they represent a first for personalized medicine in oncology. If confirmed, this could shift standard-of-care paradigms and accelerate investment in personalized immunotherapies.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works